Kamada Ltd
Research Kamada Ltd (KMDA) on Bullrun: valuation model: 0.9% overvalued, market cap USD 424.57M, P/E 21.1, dividend yield 3.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKMDA
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal0.9% overvalued
- Market capUSD 424.57M
- P/E21.1
- Dividend yield3.4%
- Financial periodQ1 2026
- RevenueUSD 45.24M
- Net incomeUSD 4.13M
- Free cash flowUSD 16.36M
- Gross margin42.3%
Valuation Snapshot
Bullrun's latest valuation model marks Kamada Ltd as 0.9% overvalued; latest market cap is USD 424.57M; P/E is 21.1; dividend yield is 3.4%.
About Kamada Ltd
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis;
Frequently asked questions
Is Kamada Ltd overvalued or undervalued?
Bullrun's valuation model currently marks Kamada Ltd as 0.9% overvalued.
What is Kamada Ltd's market cap?
Kamada Ltd's market capitalization is USD 424.57M.
What is Kamada Ltd's P/E ratio?
Kamada Ltd's price-to-earnings (P/E) ratio is 21.1.
Does Kamada Ltd pay a dividend?
Kamada Ltd has a dividend yield of 3.4%.
What does Kamada Ltd do?
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants;